1

Healthcare Costs and InnovationHealthcare Costs and InnovationCapitalizing on DNA-Guided MedicineCapitalizing on DNA-Guided Medicine

January 8, 2008

Robert W. ScherrerVice President and Chief Financial Officer

Genomas, Inc.

Economic Summit and Outlook Conference

2

Hartford Hospital, IOL, CLP, THOCC, NIHHartford Hospital, IOL, CLP, THOCC, NIH

Genomas Partners for DNA-Guided MedicineGenomas Partners for DNA-Guided Medicine

DNA-Guided Medicine: DNA-Guided Medicine: Cardiology Cardiology

PsychiatryPsychiatry DiabetesDiabetes

Equity InvestmentsEquity Investments

Co-owned Intellectual Co-owned Intellectual Property and LicensingProperty and Licensing

Clinical ApplicationsClinical Applications

Product Prototyping Product Prototyping

Research GrantsResearch Grants

$8.8 Million Raised$8.8 Million Raised

EQUITY FUNDS: $5.3MEQUITY FUNDS: $5.3M

$500K from Hartford Hospital$500K from Hartford Hospital

$500K from Hosp. Central CT$500K from Hosp. Central CT

$1.2M from Angels$1.2M from Angels

$0.6M from Founder/Mgm’t$0.6M from Founder/Mgm’t

$2.5M Series C $2.5M Series C

NON-EQUITY FUNDS: $3.5MNON-EQUITY FUNDS: $3.5M

$200K equipment loan from CT $200K equipment loan from CT Dept. Economic Dev.Dept. Economic Dev.

$300K Research Contracts$300K Research Contracts

$3.0M NIH SBIR Grants$3.0M NIH SBIR Grants

20062006

20042004

20052005

NIH SBIRStatin/AntipsychoticStatin/AntipsychoticPhase II & Fast trackPhase II & Fast track

20072007

3

Overview and Technology HighlightsOverview and Technology HighlightsAccomplished executionAccomplished execution

PRODUCTSPRODUCTS

• PhyzioType™ Systems targeting safety of psychotropic and statin drugs at prototype stage

• CLIA-certified, licensed lab for initial product support

TECHNOLOGY PLATFORMTECHNOLOGY PLATFORM

• Proven, clinically-based, PhysioGenomics Technology: multi-gene DNA marker ensembles + biostatistical algorithm

• 5,000 patient repository and database in Cardiometabolic and Psychiatric Medicine

• Applied successfully to 8 drugs, 2 diets, exercise, MRI

INTELLECTUAL PROPERTYINTELLECTUAL PROPERTY

• 5 Patent applications on PhyzioType Systems and PhysioGenomics Technology

• 19 Scientific publications• $3M SBIR NIH Grants

4

LPH Laboratory of Personalized HealthClinical Lab, High Complexity DNA Typing

• Licensed by Licensed by CT Dept of Public CT Dept of Public HealthHealth (CL-0644) (CL-0644)

• CLIA registered CLIA registered (ID # 07D1036625 Clinical Laboratory (ID # 07D1036625 Clinical Laboratory Improvement Amendments) Improvement Amendments)

Centers Medicare and Medicaid (CMS)Centers Medicare and Medicaid (CMS)

• One of the pioneering One of the pioneering DNA typing centersDNA typing centers

Exercise-induced change in large HDLIncr.

0

decr.

Subjects (n = 62)

SN

Ps

(n

= 3

84)

In operation since October 2005CYP 2D6+2C9+2C19, VKORC1

Psych Drugs, Warfarin, Tamoxifen

50 doctors served300 patients referred900 DNA Typing tests

LABORATORY OF LABORATORY OF PERSONALIZED PERSONALIZED

HEALTHHEALTH

LPHH

5

Target Markets in Drug SafetyTarget Markets in Drug Safety Statins and PsychotropicsStatins and Psychotropics

Psychotropic Psychotropic DiabetesDiabetes

• Diabetic Metabolic Symptoms, 25%

• $1.4 B settlements by Lilly 2005-2007, War-ning Diabetic risk 2004

• 6 mil patients 2010

• Indications: psychosis bipolar disorder, OCD, major anxiety

• ZyprexaZyprexa®®, Risperdal, Risperdal®®, , SeroquelSeroquel®®, $6B mkt

• Target mkt: 600K patients (10%) on antipsychotics

DiMSDiMSSIMSIMStatin Induced Statin Induced

Myopathy Myopathy

• Neuromuscular Side Effects, 20%

• $1.2B settlement by Bayer 2006, BaycolBaycol®® withdrawal 2001

• 30 mil patients 2010

• Indications: post MI, diabetes, CAD, CV risk, aggressive lipid control

• LipitorLipitor®®, Zocor, Zocor®®, , CrestorCrestor®®, $13B mkt

• Target mkt: 1.5 mil (5%) on statin high-dose > 40 mg/day

6

PhyzioType SystemsPhyzioType SystemsMedical Device for DNA-Guided MedicineMedical Device for DNA-Guided Medicine

P P H Y Z I OH Y Z I O T T Y P EY P E S S Y S T E M SY S T E M S

SNP EnsembleSNP EnsembleAssaysAssays

PHPP

P E R S O N A L I Z E D H E A L T H

P O R T A L

PhysicianPhysicianInterfaceInterface

23

32

02

12

6 21

92

22

71

45

29

26

21

52

25

23

82

17

24

01

69

55

81

58

14

91

10

74

50

12

11

04

54

20

02

18

16

82

41

10

52

14

14

81

91

80

13

22

16

16

34

70

CR

-1

C2

SB

12

78

9

SB

15

01

SB

18

25

C3

C1

SB

15

41

SB

17

27

SB

14

61

SB

12

78

1

SB

30

39

BiomathematicalBiomathematicalAlgorithmsAlgorithms

7

PhyzioType Systems: DiMSPhyzioType Systems: DiMSPredicting Weight Side Effect, Patient LPH1Predicting Weight Side Effect, Patient LPH1

Patient LPH1 on ZyprexaPatient LPH1 on Zyprexa®®

• Clinical Symptoms: Clinical Symptoms: 8 kg weight gain and 8 kg weight gain and abnormal lipids abnormal lipids • Referred to LPH and IOL Referred to LPH and IOL for DNA typing of drug for DNA typing of drug metabolism statusmetabolism status• PhyzioType Diagnosis: PhyzioType Diagnosis: Psychotropic DiMSPsychotropic DiMS

RisperdalRisperdal®® is predicted to is predicted to have the least weighthave the least weight

gain for this patient and gain for this patient and ZyprexaZyprexa®® the most. the most.

LPH1 LPH1 is hereis here

ZyprexaZyprexa

LPH1 LPH1 is here is here

RisperdalRisperdal

8

Applications of PhyzioType SystemsApplications of PhyzioType SystemsDiagnostics for DNA-Guided Drug TherapyDiagnostics for DNA-Guided Drug Therapy

P P H Y Z I OH Y Z I O T T Y P EY P E S S Y S T E M SY S T E M S

Side Effect Differential DxSide Effect Differential Dx• Patient has taken a prescribed drug and manifested side effect• PhyzioType used to diagnose likely cause of side effect based on innate genetic factors• Allows doctor to clarify etiology of symptoms versus confounding factors (mental status, physical activity, polypharmacy)

Side Effect PreventionSide Effect Prevention• PhyzioType allows doctor to prescribe drugs according to patient’s individualized drug risk • IF SIDE EFFECT RISK IS LOW: Prescribe drug w. safeguard• IF SIDE EFFECT RISK IS HIGH: Reduce drug dose Switch to other drugs Proactively monitor/treat

9

DNA-Guided MedicineDNA-Guided MedicineEnvisioning a New Kind of HealthcareEnvisioning a New Kind of Healthcare

“We can see the possibility of health care

that is increasingly calibrated to each

patient and personally effective for each

individual”

Michael O. LeavittSecretary of HHSSeptember 2007

10

Healthcare Costs Healthcare Costs and Innovatiionand Innovatiion

DNA-Guided Medicine

www.genomas.net